Arteris Q4 revenue rises 30%, beats estimates

Reuters
02/13
Arteris Q4 revenue rises 30%, beats estimates

Overview

  • Semiconductor technology provider's Q4 revenue rose 30%, beating analysts' expectations

  • Adjusted net loss came in less than analysts' expectations

  • Company completed acquisition of Cycuity for semiconductor security verification

Outlook

  • Arteris projects Q1 2026 revenue between $20.5 mln and $21.5 mln

  • Company expects FY 2026 revenue between $89 mln and $93 mln

  • Arteris sees FY 2026 ACV plus royalties between $100 mln and $104 mln

Result Drivers

  • RECORD ACV AND ROYALTIES - Arteris achieved a record Annual Contract Value plus royalties of $83.6 mln, representing 28% growth year-over-year

  • ROYALTY GROWTH - Company recorded 50% year-over-year growth in royalties, driven by over four billion systems shipped with Arteris System IP

  • CYCUITY ACQUISITION - Acquisition of Cycuity strengthens Arteris' ability to secure data movement in silicon, addressing cybersecurity threats

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Revenue

Beat

$20.10 mln

$18.55 mln (4 Analysts)

Q4 Adjusted Net Income

Beat

-$2.30 mln

-$2.72 mln (3 Analysts)

Q4 Net Income

-$8.50 mln

Q4 Adjusted Operating Income

Beat

-$2.20 mln

-$2.66 mln (4 Analysts)

Q4 Operating Income

-$8.50 mln

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the software peer group is "buy"

  • Wall Street's median 12-month price target for Arteris Inc is $20.50, about 35.8% above its February 11 closing price of $15.10

Press Release: ID:nGNX6pzDmW

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10